[go: up one dir, main page]

RU2717238C2 - Соединения 1-циано-пирролидинов в качестве ингибиторов USP30 - Google Patents

Соединения 1-циано-пирролидинов в качестве ингибиторов USP30 Download PDF

Info

Publication number
RU2717238C2
RU2717238C2 RU2017134901A RU2017134901A RU2717238C2 RU 2717238 C2 RU2717238 C2 RU 2717238C2 RU 2017134901 A RU2017134901 A RU 2017134901A RU 2017134901 A RU2017134901 A RU 2017134901A RU 2717238 C2 RU2717238 C2 RU 2717238C2
Authority
RU
Russia
Prior art keywords
cyanopyrrolidin
carboxamide
methyl
pyrazol
benzamide
Prior art date
Application number
RU2017134901A
Other languages
English (en)
Russian (ru)
Other versions
RU2017134901A (ru
RU2017134901A3 (fr
Inventor
Элисон ДЖОНС
Марк КЕМП
Мартин СТОКЛИ
Карл ГИБСОН
Гэвин УИТЛОК
Original Assignee
Мишн Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1505429.9A external-priority patent/GB201505429D0/en
Priority claimed from GBGB1512829.1A external-priority patent/GB201512829D0/en
Application filed by Мишн Терапьютикс Лимитед filed Critical Мишн Терапьютикс Лимитед
Publication of RU2017134901A publication Critical patent/RU2017134901A/ru
Publication of RU2017134901A3 publication Critical patent/RU2017134901A3/ru
Application granted granted Critical
Publication of RU2717238C2 publication Critical patent/RU2717238C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
RU2017134901A 2015-03-30 2016-03-24 Соединения 1-циано-пирролидинов в качестве ингибиторов USP30 RU2717238C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1505429.9A GB201505429D0 (en) 2015-03-30 2015-03-30 Novel compounds
GB1505429.9 2015-03-30
GBGB1512829.1A GB201512829D0 (en) 2015-07-21 2015-07-21 Novel compounds
GB1512829.1 2015-07-21
PCT/GB2016/050851 WO2016156816A1 (fr) 2015-03-30 2016-03-24 Composés 1-cyano-pyrrolidine utilisés comme inhibiteurs d'usp30

Publications (3)

Publication Number Publication Date
RU2017134901A RU2017134901A (ru) 2019-04-30
RU2017134901A3 RU2017134901A3 (fr) 2019-06-25
RU2717238C2 true RU2717238C2 (ru) 2020-03-19

Family

ID=55646790

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134901A RU2717238C2 (ru) 2015-03-30 2016-03-24 Соединения 1-циано-пирролидинов в качестве ингибиторов USP30

Country Status (29)

Country Link
US (6) US10343992B2 (fr)
EP (3) EP3277677B9 (fr)
JP (3) JP6708661B2 (fr)
KR (1) KR102578325B1 (fr)
CN (2) CN112707893B (fr)
AU (1) AU2016240033B2 (fr)
BR (1) BR112017020900B1 (fr)
CA (1) CA2976741C (fr)
CO (1) CO2017011172A2 (fr)
CY (1) CY1124170T1 (fr)
DK (1) DK3277677T3 (fr)
ES (1) ES2864950T3 (fr)
HR (1) HRP20210791T2 (fr)
HU (1) HUE054474T2 (fr)
IL (1) IL254721B (fr)
LT (1) LT3277677T (fr)
MD (1) MD3277677T2 (fr)
MX (1) MX373656B (fr)
MY (1) MY188957A (fr)
NZ (1) NZ736450A (fr)
PL (1) PL3277677T3 (fr)
PT (1) PT3277677T (fr)
RS (1) RS61759B9 (fr)
RU (1) RU2717238C2 (fr)
SG (1) SG11201706542TA (fr)
SI (1) SI3277677T1 (fr)
SM (1) SMT202100287T1 (fr)
WO (1) WO2016156816A1 (fr)
ZA (1) ZA201705717B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
SG11201706542TA (en) * 2015-03-30 2017-10-30 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
WO2018213150A1 (fr) * 2017-05-15 2018-11-22 Mitobridge, Inc. Inhibiteurs de usp30
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
WO2018234775A1 (fr) * 2017-06-20 2018-12-27 Mission Therapeutics Limited Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub
EP3692028B1 (fr) 2017-10-06 2023-04-26 Forma Therapeutics, Inc. Inhibition de la peptidase 30 spécifique de l'ubiquitine
US12049466B2 (en) 2018-05-17 2024-07-30 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
WO2020036940A1 (fr) 2018-08-14 2020-02-20 Amgen Inc. Dérivés de n-cyano-7-azanorbordane et leurs utilisations
PT3860989T (pt) * 2018-10-05 2023-06-30 Forma Therapeutics Inc Pirrolinas fundidas que atuam como inibidores da protease 30 específica da ubiquitina (usp30)
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
WO2021202600A1 (fr) * 2020-03-30 2021-10-07 The Scripps Research Institute Inhibiteurs à petites molécules de l'hémagglutinine de la grippe
CN111303128B (zh) * 2020-04-07 2020-10-27 苏州信诺维医药科技有限公司 一种多环类化合物、其制备方法及应用
MX2022012578A (es) * 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
CA3185027A1 (fr) * 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3- (trifluoromethyl)phenyl)oxazole-2-carboxamide et derives d'oxadiazole correspondants utilises en tant qu'inhibiteurs d'usp30 pour le traitement d 'un dysfonctionnement mitochondrial
WO2021245186A1 (fr) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines ayant une activité en tant qu'inhibiteurs de l'usp30
SI4161929T1 (sl) * 2020-06-08 2025-10-30 Mission Therapeutics Limited 1-(5-(2-cianopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kot zaviralec usp30 za uporabo pri zdravljenju mitohondrijske disfunkcije, raka in fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
US20240059673A1 (en) * 2020-12-22 2024-02-22 Gilead Sciences, Inc. Substituted indole compounds
EP4323369A1 (fr) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Composés de thiénopyrrole
CN117957234A (zh) 2021-09-10 2024-04-30 吉利德科学公司 噻吩并吡咯化合物
AU2022362107A1 (en) 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
EP4604947A2 (fr) * 2022-10-19 2025-08-27 Ohio State Innovation Foundation Compositions et méthodes pour prévenir la cardiomyopathie
WO2024182384A1 (fr) * 2023-02-28 2024-09-06 Cyteir Therapeutics, Inc. Composés pyrrolidine et pyrrolidinone substitués
CN119528901A (zh) * 2024-11-05 2025-02-28 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (fr) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Inhibiteurs de proteases a cysteine de type cathepsines
WO2006091646A2 (fr) * 2005-02-22 2006-08-31 The Regents Of The University Of Michigan Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
WO2009129371A1 (fr) * 2008-04-18 2009-10-22 Glaxo Group Limited Inhibiteurs de la cathepsine c
US20120077806A1 (en) * 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase Inhibitors and Methods for Use of the Same
RU2564022C2 (ru) * 2010-02-09 2015-09-27 Ф.Хоффманн-Ля Рош Аг Замещенные пирролидин-2-карбоксамиды
EA026409B1 (ru) * 2011-10-19 2017-04-28 Виволюкс Аб Соединение, ингибирующее деубиквитинирующую активность, и использование его в композиции и в способе лечения рака

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO2004022536A1 (fr) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited Nouveaux composes amides heterocycliques utilises pour le traitement d'affections inflammatoires et allergiques; procede permettant de les fabriquer et compositions pharmaceutiques les contenant
JP5507552B2 (ja) 2008-06-16 2014-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌を処置するための化合物
JP5592388B2 (ja) 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野
EP2410858B1 (fr) 2009-03-23 2016-09-07 Merck Sharp & Dohme Corp. Antagonistes du récepteur p2x3 pour le traitement de la douleur
AU2013207900B2 (en) * 2012-01-12 2017-12-07 Cambridge Enterprise Limited Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
MX364438B (es) 2013-03-15 2019-04-26 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
WO2016019237A2 (fr) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
SG11201706542TA (en) * 2015-03-30 2017-10-30 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (fr) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines en tant qu'inhibiteurs des dub pour le traitement du cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
ES2850349T3 (es) * 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (fr) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Inhibiteurs de proteases a cysteine de type cathepsines
WO2006091646A2 (fr) * 2005-02-22 2006-08-31 The Regents Of The University Of Michigan Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
WO2009129371A1 (fr) * 2008-04-18 2009-10-22 Glaxo Group Limited Inhibiteurs de la cathepsine c
RU2564022C2 (ru) * 2010-02-09 2015-09-27 Ф.Хоффманн-Ля Рош Аг Замещенные пирролидин-2-карбоксамиды
US20120077806A1 (en) * 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase Inhibitors and Methods for Use of the Same
EA026409B1 (ru) * 2011-10-19 2017-04-28 Виволюкс Аб Соединение, ингибирующее деубиквитинирующую активность, и использование его в композиции и в способе лечения рака

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Falgueyret, J.-P., Oballa, R. M., Okamoto, O., Wesolowski, G., Aubin, Y., Rydzewski, R. M. Percival, M. D. (2001). Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L. Journal of Medicinal Chemistry, 44(1), 94-104. doi:10.1021/jm0003440. *
Falgueyret, J.-P., Oballa, R. M., Okamoto, O., Wesolowski, G., Aubin, Y., Rydzewski, R. M. Percival, M. D. (2001). Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L. Journal of Medicinal Chemistry, 44(1), 94-104. doi:10.1021/jm0003440. Lainé, D., Palovich, M., McCleland, B., Petitjean, E., Delhom, I., Xie, H. Bettoun, D. (2010). Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C. ACS Medicinal Chemistry Letters, 2(2), 142-147. doi:10.1021/ml100212k. *
Lainé, D., Palovich, M., McCleland, B., Petitjean, E., Delhom, I., Xie, H. Bettoun, D. (2010). Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C. ACS Medicinal Chemistry Letters, 2(2), 142-147. doi:10.1021/ml100212k *

Also Published As

Publication number Publication date
JP6708661B2 (ja) 2020-06-10
CN112707893A (zh) 2021-04-27
US20190284138A1 (en) 2019-09-19
JP2018510183A (ja) 2018-04-12
US11066365B2 (en) 2021-07-20
CN107484415A (zh) 2017-12-15
LT3277677T (lt) 2021-05-25
MD3277677T2 (ro) 2021-07-31
IL254721B (en) 2019-12-31
ES2864950T9 (es) 2021-11-18
ZA201705717B (en) 2019-09-25
ES2864950T3 (es) 2021-10-14
AU2016240033A1 (en) 2017-11-09
RU2017134901A (ru) 2019-04-30
CN112707893B (zh) 2023-10-31
WO2016156816A1 (fr) 2016-10-06
IL254721A0 (en) 2017-11-30
MY188957A (en) 2022-01-14
CO2017011172A2 (es) 2018-01-16
EP3842427A1 (fr) 2021-06-30
US20220251041A1 (en) 2022-08-11
RS61759B1 (sr) 2021-05-31
EP3277677B1 (fr) 2021-02-24
CA2976741A1 (fr) 2016-10-06
US10689345B2 (en) 2020-06-23
MX2017012566A (es) 2018-01-25
US10343992B2 (en) 2019-07-09
JP7389856B2 (ja) 2023-11-30
SG11201706542TA (en) 2017-10-30
US20180086708A1 (en) 2018-03-29
KR102578325B1 (ko) 2023-09-15
EP3277677A1 (fr) 2018-02-07
EP3943490A1 (fr) 2022-01-26
SI3277677T1 (sl) 2021-08-31
DK3277677T3 (da) 2021-05-25
CY1124170T1 (el) 2022-05-27
US20190322624A1 (en) 2019-10-24
HRP20210791T2 (hr) 2021-12-10
RU2017134901A3 (fr) 2019-06-25
PT3277677T (pt) 2021-04-20
MX373656B (es) 2020-04-02
NZ736450A (en) 2022-04-29
US20200181086A1 (en) 2020-06-11
AU2016240033B2 (en) 2020-04-16
JP2020143124A (ja) 2020-09-10
JP2022123095A (ja) 2022-08-23
EP3277677B9 (fr) 2021-07-14
PL3277677T3 (pl) 2021-08-30
BR112017020900A2 (pt) 2018-07-10
BR112017020900B1 (pt) 2023-02-23
CN107484415B (zh) 2021-01-29
KR20170131654A (ko) 2017-11-29
HRP20210791T1 (hr) 2021-06-25
SMT202100287T1 (it) 2021-07-12
US11053198B2 (en) 2021-07-06
US11390584B2 (en) 2022-07-19
US20190270708A1 (en) 2019-09-05
HK1245266A1 (zh) 2018-08-24
CA2976741C (fr) 2023-01-17
RS61759B9 (sr) 2021-11-30
JP7216682B2 (ja) 2023-02-01
HUE054474T2 (hu) 2021-09-28

Similar Documents

Publication Publication Date Title
RU2717238C2 (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
EP3197883B1 (fr) Nouveaux composés
ES2864948T3 (es) Aparato de colocación de remaches ciegos y dispositivo de procesamiento de remaches ciegos con un aparato de colocación de remaches ciegos
HK40043421A (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
HK1245266B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物